Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity
SEA Burnell, L Capitani, BJ MacLachlan… - Immunotherapy …, 2022 - academic.oup.com
Despite three decades of research to its name and increasing interest in immunotherapies
that target it, LAG-3 remains an elusive co-inhibitory receptor in comparison to the well …
that target it, LAG-3 remains an elusive co-inhibitory receptor in comparison to the well …
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel
Although anti-CD19 chimeric antigen receptor (CAR) T-cell therapy produces high response
rates and durable remissions in patients with large B-cell lymphoma (LBCL), relapses can …
rates and durable remissions in patients with large B-cell lymphoma (LBCL), relapses can …
CD19-directed CAR T-cell therapy in B-cell NHL
MJ Kersten, AM Spanjaart… - Current opinion in …, 2020 - journals.lww.com
CD19-directed CAR T-cell therapy in B-cell NHL : Current Opinion in Oncology CD19-directed
CAR T-cell therapy in B-cell NHL : Current Opinion in Oncology Log in or Register Subscribe to …
CAR T-cell therapy in B-cell NHL : Current Opinion in Oncology Log in or Register Subscribe to …
Mechanisms of resistance to chimeric antigen receptor t cell therapy
GA Johnson, FL Locke - Hematology/Oncology Clinics, 2023 - hemonc.theclinics.com
Background Chimeric antigen receptor (CAR) T-cell therapy has proved effective for putting
both indolent and aggressive malignancies into remissions that endure longer than former …
both indolent and aggressive malignancies into remissions that endure longer than former …
Chimeric antigen receptor T-cell therapy for solid tumors
Chimeric antigen receptor (CAR) T-cell studies in the 1990s initially focused on solid tumors,
1, 2 and the first human trials of CAR-Ts in 2006 were conducted in patients with ovarian 3 …
1, 2 and the first human trials of CAR-Ts in 2006 were conducted in patients with ovarian 3 …
[PDF][PDF] The Role of Tumor Microenvironment in T Cell Redirecting Therapies of Large B Cell Lymphoma: Translating Lessons Learned from CAR-T to Bispecific …
KV Lepik, VV Markelov - 2024 - preprints.org
T-cell redirecting therapies, which include chimeric antigen receptor T-cells (CAR-T) and
bispecific antibodies (BSAs), have revolutionized the treatment of relapsed\refractory large B …
bispecific antibodies (BSAs), have revolutionized the treatment of relapsed\refractory large B …